INTRODUCTION

• Tumor necrosis factor-α inhibitors (TNFi), including adalimumab, certolizumab pegol, etanercept, golimumab, and infliximab, are first-line therapy for the treatment of psoriatic arthritis and moderate-to-severe psoriasis.1
• Treatment discontinuation is usually followed by disease relapse, and persistence of biologic therapy is a surrogate for efficacy and safety of treatment.1
• Previous studies on TNF discontinuation rates in psoriatic arthritis patients are varied.1-3

OBJECTIVE

This study aims to compare discontinuation rates across the five TNFis with associations with patient characteristics, as well as identify reasons for discontinuation of TNF in patients with psoriasis and/or psoriatic arthritis.

METHODS

Study design: A retrospective analysis of the Program to Understand the Longterm Outcomes in SpondyloArthritis (PULSAR) cohort was performed. PULSAR is a prospective, longitudinal registry and biopsychosocial with medical and demographic data for over 1200 rheumatology patients at Veterans Affairs Medical Centers (VAMC).

Participants: Subjects with psoriatic arthritis and/or psoriasis, who received a TNFi from the VAMC from 2007-2017, were included for analysis.

Statistical methods: Univariate and multivariate analysis of the characteristics of patients who discontinued a TNFi at 12 months were conducted using Stata. Stata was also used to conduct a time to event analysis of drug persistence over 3 years. Discontinuation of a biologic course was defined as the length of follow-up such that it was not possible to survive the entire study period.

RESULTS

320 individuals with 927 TNFi courses, including adalimumab (N = 378), certolizumab (N = 24), etanercept (N = 396), golimumab (N = 42), and infliximab (N = 87), were available for analysis. 243 of these patients also had both psoriasis and psoriatic arthritis. 16.2% of subjects discontinued at least one TNFi course at one year, and 35.6% discontinued at two years.

DISCUSSION

Figure 1: TNFi Persistence in Psoriasis and Psoriatic Arthritis (Adjusted for Course Order)

Table 1: Characteristics of TNFi Discontinuation

Table 2: Discontinuation of Tumor Necrosis Factor Inhibitor (TNFi) Compared to Infliximab

REFERENCES


Disclosures: S. Wolfe, None; E. Cheng, None; K. Ganuthula, None; M. Fang, None; K. Aurinia, S. Novartis, S. Bristol Myers Squibb, S. Pfizer, H. Horizon, J. D. Walsh, Abbvie, S. Merck, S. Pfizer, Z. UCSB, S. Eli Lilly, S. Novartis, S. A. Amgen, S. E. Chang, None; B. Raychaudhuri, Johnson & Johnson, S. Abbvie, S. 6. Sun Pharma, S. UCSB company, I. Novartis, S. Pfizer, S. K. Brees. None; R. Dellalene, None; A. Reimold, None; L. Caplan, None.